Recursion Pharmaceuticals Inc vs Yum China Holdings Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Yum China Holdings Inc trades at $43.91 (market cap $15.09B). The key difference: Yum China Holdings Inc is far larger — about 9.9× Recursion Pharmaceuticals Inc's market cap, and Yum China Holdings Inc pays a 2.64% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | YUMC | |
|---|---|---|
Market Cap | $1.53B | $15.09B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $57.95 |
52-Week Low | $2.84 | $40.18 |
Enterprise Value | $946.50M | $15.98B |
Dividend Yield | — | 2.64% |
Trailing returns across standard periods
Latest headlines on both assets
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →